Pfizer shares climb 1.15 percent

By Sumit Modi

Shares of New York-based pharmaceutical company Pfizer have increased 1.15 percent to $37.31 as it prepares to release this year's second quarter earnings later today.

It is expected that the earnings will reach around 62 cents on revenue of $13.01 billion. This time last year, earnings were 56 cents on revenue of $11.85 billion.

Pfizer also announced this week that it has acquired Bamboo Theapeutics for $150 million, expanding its gene therapy biotechnology expertise. 

Pfizer will take over Bamboo's manufacturing facility and any treatments which are currently in development. It had previously collaborated with Spark Therapeutics to create a treatment for hemophilia B.

According to The Street, Mikael Dolsten, Head of Research and Development at Pfizer, said: "We believe that gene therapy holds the promise of bringing true disease modification for patients suffering from devastating diseases."


Follow @BizReviewUSA and @NellWalkerMG

Read the July issue of Business Review USA & Canada here


Featured Articles

Patagonia Chair Charles Conn on becoming an imperfectionist

Entrepreneur and Patagonia Chair Charles Conn talks to Business Chief about rethinking strategy amid uncertainty, and why an imperfectionist approach works

Top 10 most valuable brands in the world – Amazon to TikTok

Business Chief takes a look at the top 10 most valuable brands in the world, according to Brand Finance, which puts 5,000 major companies to the test

Four priorities for new Twitter CEO Linda Yaccarino

Elon Musk confirmed on Friday that Linda Yaccarino, who most recently worked as Chairman of Global Advertising at NBCU, would become Twitter's new CEO

Top 10 shifts transforming organisations – McKinsey & Co

Leadership & Strategy

Top 10 fastest-growing jobs in the world according to WEF

Technology & AI

Top 10 female Chief Information Officers in North America

Digital Strategy